Acupuncture Therapy in Patients With Subacromial Impingement Syndrome
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05794633 |
Recruitment Status :
Not yet recruiting
First Posted : April 3, 2023
Last Update Posted : September 14, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acupuncture Subacromial Impingement Syndrome | Other: Acupuncture Other: Placebo acupuncture | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 80 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Randomized placebo-controlled trial |
Masking: | Double (Participant, Outcomes Assessor) |
Masking Description: | All patients will be evaluated by the same physiatrist who are blinded to the randomization process and treatment protocols |
Primary Purpose: | Treatment |
Official Title: | Effectiveness of Acupuncture Therapy in Patients With Subacromial Impingement Syndrome, Randomized Placebo-controlled Trial |
Estimated Study Start Date : | September 12, 2023 |
Estimated Primary Completion Date : | November 20, 2023 |
Estimated Study Completion Date : | January 20, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Acupuncture Group
The patients will be recieved two days a week for 8 sessions with sterile 25*40 mm needles.Selected points are as local points, 2 painful points (ahshi point) in the shoulder region, Large intestine 4, 15, Gallbladder 21, Triple warmer 5, 14 Small intestine 9; as distant points Gallbladder 34 and Stomach 38. Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks |
Other: Acupuncture
The patients will be recieved two days a week for 8 sessions with sterile 25*40 mm needles.Selected points are as local points, 2 painful points (ahshi point) in the shoulder region, Large intestine 4, 15, Gallbladder 21, Triple warmer 5, 14 Small intestine 9; as distant points Gallbladder 34 and Stomach 38. Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks |
Placebo Comparator: Placebo Acupuncture Group
The patients will be recieved two days a week for 8 sessions with placebo needle. Selected points are Large intestine 15 Triple warmer 14 gallbladder 21 and small intestine 9. We will use the Placebo needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time will be the same as those in the acupuncture group. The specialist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other. Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks |
Other: Placebo acupuncture
The patients will be recieved two days a week for 8 sessions with placebo needle. Selected points are Large intestine 15 Triple warmer 14 gallbladder 21 and small intestine 9. We will use the placebo needle (blunt needle, tip obtuse, when acupuncture the feeling is similar to acupuncture needles into the skin, but it retracts instead of piercing the skin) to conduct acupuncture treatment. The retention time will be the same as those in the acupuncture group. The specialist will give the subjects verbal cues before and during the acupuncture manipulation, which further reduces the subjects' doubts about the authenticity of acupuncture in the this group. To ensure the implementation of the blinding method, all patients will be treated independently and avoid contacting with each other. Patients will recieve also exercise treatment for 8 weeks and coldpack for 4 weeks |
- Pain intensity [ Time Frame: 2 months ]All groups will be evaluated for shoulder pain with visual analogue scale (VAS) for rest, activity, and sleep-disturbing.
- Shoulder Pain and Disability Index [ Time Frame: 2 months ]All groups will be evaluated for shoulder function with the Shoulder Pain and Disability Index (SPADI). SPADI:The pain dimension consists of five questions regarding the severity of an individual's pain. Functional activities are assessed with eight questions designed to measure the degree of difficulty an individual has with various activities of daily living that require upper-extremity use. To answer the questions, patients place a mark on a 10cm visual analogue scale for each question. Higher results indicate worse function.
- The Disabilities of the Arm, Shoulder and Hand Score [ Time Frame: 2 months ]All groups will be evaluated for shoulder function with The Disabilities of the Arm, Shoulder and Hand Score (QuickDash). The QuickDASH only contains 11 items. It is a questionnaire that measures an individual's ability to complete tasks, absorb forces, and severity of symptoms. The QuickDASH tool uses a 5-point Likert scale from which the patient can select an appropriate number corresponding to his/her severity/function level. Higher results indicate worse function.
- Shoulder range of motion [ Time Frame: 2 months ]All groups will be evaluated for shoulder range of motion with goniometer.
- Quality of life index [ Time Frame: 2 months ]Quality of life: All groups will be evaluated for quality of life with The Western Ontario Rotator Cuff Index (WORC). Each item in WORC has a possible score from 0-100 (100mm VAS). Scores can be computed for individual subscales and summated for a total score, which can range from 0-2100, with a higher score representing lower quality of life.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Clinical diagnosis of Subacromial impingement syndrome
- Age range from 20-65 years
- Pain VAS ≥ 4
- Shoulder impingement symptoms lasting at least 6 weeks
Exclusion Criteria:
- Presence of other shoulder pathologies
- Previous applications of physiotherapy and injection of hyaluronic acid and/or corticosteroid during the preceding 3 months;
- Presence of cervical pain or other conditions such as fibromyalgia confusing the clinical picture
- Presence of malignancy, blood disorder, neurologic, motor, and/or sensory deficit in the upper extremity;
- Pregnancy,
- Local anesthetic allergy
- Previous acupuncture treatment
- History of deformities, fractures, or surgery of the shoulder

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05794633
Contact: Duygu Silte Karamanlioglu | 00905323074990 | drduygusilte@hotmail.com |
Principal Investigator: | Duygu Silte Karamanlioglu | Fatih Sultan Mehmet Traning and Research Hospital | |
Study Chair: | Meryem Yilmaz Kaysin | Fatih Sultan Mehmet Traning and Research Hospital | |
Study Chair: | Feyza Akan Begoglu | Fatih Sultan Mehmet Traning and Research Hospital | |
Study Chair: | Pinar Akpinar | Fatih Sultan Mehmet Traning and Research Hospital | |
Study Chair: | Feyza Unlu Ozkan | Fatih Sultan Mehmet Traning and Research Hospital | |
Study Chair: | Ilknur Aktas | Fatih Sultan Mehmet Traning and Research Hospital |
Responsible Party: | Duygu Karamanlıoğlu, Principal investigator, Fatih Sultan Mehmet Training and Research Hospital |
ClinicalTrials.gov Identifier: | NCT05794633 |
Other Study ID Numbers: |
KAEK-2012-70 |
First Posted: | April 3, 2023 Key Record Dates |
Last Update Posted: | September 14, 2023 |
Last Verified: | September 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Shoulder Impingement Syndrome Syndrome Rotator Cuff Injuries Disease Pathologic Processes Rupture |
Wounds and Injuries Shoulder Injuries Tendon Injuries Joint Diseases Musculoskeletal Diseases |